Search

Denali Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

24.8 2.65

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

23.4

Max

24.9

Galvenie mērījumi

By Trading Economics

Ienākumi

894K

-128M

Pārdošana

3.6M

3.6M

EPS

-0.68

Peļņas marža

-3,539.206

Darbinieki

503

EBITDA

1.6M

-124M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+44.46% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

218M

3.9B

Iepriekšējā atvēršanas cena

22.15

Iepriekšējā slēgšanas cena

24.8

Ziņu noskaņojums

By Acuity

25%

75%

73 / 340 Rangs Healthcare

Denali Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. aug. 22:46 UTC

Denali Therapeutics Inc's shares are higher in after-market trading, reflecting a cumulative gain since Monday's close. No specific news was identified for this movement.

2026. g. 20. aug. 19:16 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower today, reflecting broader market trends. The stock has declined since Wednesday amid volatility in biotech and small-cap indices.

2026. g. 19. aug. 20:02 UTC

Correlated Moves

DNLI is higher Wednesday, recovering with the SPDR S&P Biotech ETF.

2026. g. 17. aug. 19:36 UTC

Correlated Moves

Denali Therapeutics Inc is trading higher today, supported by gains in the biotechnology sector. The stock remains near its 20-day moving average.

2026. g. 13. aug. 19:36 UTC

News

Denali Therapeutics reported Q2 revenue of $3.6 million from AVLAYAH, but shares are lower despite expectations for growth in Q3.

2026. g. 12. aug. 19:36 UTC

Denali Therapeutics Inc. shares are higher Wednesday, buoyed by positive market sentiment following a modest rise in the core Consumer Price Index.

2026. g. 11. aug. 23:21 UTC

Denali Therapeutics Inc shares are higher in after-market trading. No specific company news was identified to explain this movement.

2026. g. 10. aug. 19:36 UTC

Correlated Moves

Denali Therapeutics Inc shares declined during Monday's session, tracking broader market trends as the Russell 2000 Index fell. Energy market volatility also influenced the move.

2026. g. 7. aug. 19:26 UTC

Social Media
News

Denali Therapeutics shares are lower after a $127.6 million net loss in Q2, missing revenue expectations despite a price target increase from UBS to $34.

2026. g. 6. aug. 21:03 UTC

News

Denali Therapeutics shares rise in after-market hours following strong revenue from AVLAYAH and plans to advance Alzheimer's programs despite an EPS miss.

2026. g. 3. aug. 19:46 UTC

Correlated Moves
News

Denali Therapeutics received FDA orphan designation for its progranulin therapy for frontotemporal dementia, contributing to a modest rise in shares since Friday's close.

2026. g. 31. jūl. 20:02 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower today amid a broader decline in the Biotechnology sub-sector and the Russell 2000 Index.

2026. g. 30. jūl. 19:18 UTC

Correlated Moves

Denali Therapeutics Inc shares are higher, reflecting positive sentiment in the biotech sector amid gains in the broader market and a volatile prior session.

2026. g. 29. jūl. 22:01 UTC

Denali Therapeutics Inc remains unchanged in after-market hours with no specific news. Broader market concerns stem from geopolitical tensions and upcoming Fed decisions.

2026. g. 28. jūl. 18:46 UTC

Denali Therapeutics Inc shares are higher today, though no specific news explains the movement. The stock remains below its 20-day moving average.

2026. g. 27. jūl. 19:56 UTC

Denali Therapeutics Inc is trading higher today, reflecting a notable increase since Friday's close. The stock peaked early before a slight pullback.

2026. g. 24. jūl. 19:26 UTC

Correlated Moves

Denali Therapeutics Inc shares are lower following first-quarter results, continuing a decline amid broader market weakness and a drop in crude oil prices.

2026. g. 22. jūl. 17:46 UTC

Correlated Moves

Denali Therapeutics shares are lower, reflecting broader market trends amid a decline in the Russell 2000 Index. The stock remains below its 20-day moving average.

2026. g. 21. jūl. 17:36 UTC

Correlated Moves

Denali Therapeutics Inc is higher today, recovering from an earlier dip amid positive market sentiment driven by gains in the Russell 2000 and Nasdaq 100 indices.

2026. g. 20. jūl. 23:41 UTC

Correlated Moves

Denali Therapeutics Inc. gained in after-market trading, reflecting a broader trend among correlated assets like Beam Therapeutics Inc. Shares remain below the 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Denali Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

44.46% augšup

Prognoze 12 mēnešiem

Vidējais 36 USD  44.46%

Augstākais 42 USD

Zemākais 26 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Denali Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

14

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

73 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat